Neogen Corp (NEOG) Files 8-K: Director Changes & Compensation Updates

Ticker: NEOG · Form: 8-K · Filed: Oct 1, 2024 · CIK: 711377

Neogen Corp 8-K Filing Summary
FieldDetail
CompanyNeogen Corp (NEOG)
Form Type8-K
Filed DateOct 1, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.16
Sentimentneutral

Sentiment: neutral

Topics: board-changes, executive-compensation, governance

Related Tickers: NEOG

TL;DR

NEOG board shakeup and pay changes filed. Watch for new director impact.

AI Summary

On September 25, 2024, Neogen Corporation (NEOG) filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes the election of new directors and updates to compensatory arrangements for certain officers. Specific details regarding the individuals elected and the terms of their compensation are provided within the document.

Why It Matters

Changes in a company's board of directors and executive compensation can signal shifts in strategy, governance, or financial priorities, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect company strategy and performance.

Key Players & Entities

  • Neogen Corporation (company) — Registrant
  • NEOG (company) — Ticker Symbol
  • September 25, 2024 (date) — Date of Report

FAQ

Who were the directors elected or whose departure was reported?

The filing indicates the election of directors and potential departures, but specific names of individuals are not listed in the provided excerpt. Further details would be in the full document.

What specific changes were made to executive compensation arrangements?

The filing states that there were updates to compensatory arrangements of certain officers, but the exact nature and details of these changes are not specified in the provided excerpt.

What is Neogen Corporation's primary business?

Neogen Corporation operates in the 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES' industry, as indicated by its SIC code [2835].

When did Neogen Corporation's fiscal year end?

Neogen Corporation's fiscal year ends on May 31st.

What is the filing date of this 8-K report?

This 8-K report was filed on October 1, 2024, with the earliest event reported being September 25, 2024.

Filing Stats: 576 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-10-01 08:54:42

Key Financial Figures

  • $0.16 — nge on which registered Common Stock, $0.16 par value per share NEOG Nasdaq Glo

Filing Documents

01 Other Events

Item 8.01 Other Events. On October 1, 2024, Neogen issued a press release announcing the appointment of a new board member. A copy of this press release is furnished as Exhibit 99.1

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release dated October 1, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEOGEN CORPORATION Date: October 1, 2024 By: /s/ Amy M. Rocklin Name: Amy M. Rocklin Title: Chief Legal & Compliance Officer, Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.